Abstract
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders of the central nervous system, which predominantly affects patients’ motor functions, movement, and stability. Monitoring movement in patients with PD is crucial for inferring motor state fluctuations throughout daily life activities, which aids in disease progression analysis and assessing how patients respond to medications over time. In recent years, there has been an increase in the usage of wearable sensors for PD symptom monitoring. In this study, we present a preliminary analysis of smart glasses equipped with IMU sensors to provide objective information on the motor state in patients with PD. Data were collected from seven Parkinson’s patients with varying levels of symptom severity. The patients performed the Timed-Up-and-Go (TUG) Test while wearing IMU-equipped glasses. Our analysis indicates that smart glasses can provide information about patients’ gait that can be used to assess the severity level of the PD as measured by two standardized questionnaires. Furthermore, patient-specific clusters can be easily detected in the sensor data, hinting at the development of personalized models for patient-specific monitoring of symptom progression. Therefore, smart glasses have the potential to be used as an unobtrusive and continuous screening tool for PD patients’ gait, enhancing medical assessment and treatment.
CCS CONCEPTS • Applied computing • Life and medical sciences • Health informatics
ACM Reference Format First Author’s Name, Initials, and Last Name, Second Author’s Name, Initials, and Last Name, and Third Author’s Name, Initials, and Last Name. 2022. The Title of the Paper: ACM Conference Proceedings Manuscript Submission Template: This is the subtitle of the paper, this document both explains and embodies the submission format for authors using Word. In Woodstock ‘18: ACM Symposium on Neural Gaze Detection, June 03–05, 2018, Woodstock, NY. ACM, New York, NY, USA, 10 pages. NOTE: This block will be automatically generated when manuscripts are processed after acceptance.
Competing Interest Statement
The study was funded by emteqLabs.
Funding Statement
The study was funded by emteqLabs.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the NHS research ethics committee, (ref: 18/WM/0205) and took place at Queen Victoria Hospital in East Grinstead, England.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
martin.gjoreski{at}usi.ch, ifi.mavridou{at}emteqlabs.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors
